合成生物學:新的全球的市場 是由出版商BCC Research在2011年11月所出版的。
這份英文市場調查報告書包含279 Pages 價格從美金4850起跳。
2010年，全球合成生物學市場達到11億美元的市場規模。2011年後預計將以45.8％的年平均成長率成長，預計從2011年的16億美元到2016年的108億美元的規模將有大幅度成長。
本報告提供已上市以及5年以內預定上市的合成生物學的主要產品(合成遺傳基因·合成細胞等)，實行技術(DNA定序·寡核苷酸·生物資訊等)，整合系統，應用產品(生質燃料·特殊化學品·醫藥品等)的市場相關調查分析，產品類型·技術區分·最終消費者產業·不同地區的市場預測(∼2016年)，市場影響因素分析，並彙整主要企業簡介等，為您概述為以下內容。
第1章 簡介
第2章 摘要
第3章 概要
- 本書所談到的合成生物學的技術
- 什麼是合成生物學
- 合成生物學的發展階段
- 合成生物學市場成長推進因素
- 全球合成生物學相關產品市場潛在性
- 產品及技術的生命週期的情形
- 合成生物學產業
第4章 合成生物學的技術
- 簡介
- 合成生物學的技術:概要
- 實行技術
- 生物學的成分和整合系統的技術
- 應用技術
- 通路技術
- 合成微生物學國際集團
- Ｒ＆Ｄ應用
- 生質燃料技術
第5章 合成生物學的應用
- 簡介
- 實行技術的用途
- 生物學的因素和整合系統的應用
- 應用技術的用途
第6章 合成生物學產業
- 價值鏈
- 產業結構的因素
- 產品·技術的生命週期
- 遺傳基因合成產業
- 生質燃料產業
- 化學產業
- 酵素產業
- 醫藥品產業
第7章 合成生物學市場
- 產業成長的推進因素
- 宏觀經濟預測前提條件
- 合成生物學市場:各最終消費者產業
- 合成生物學市場:各類型產品
- 有效產品市場
- 合成生物學市場:各地區
第8章 專利
- 簡介
- 合成生物學產業的專利分析
- 主要企業的專利策略
第9章 企業簡介
圖表
Abstract
REPORT HIGHLIGHTS
- The global value of the synthetic biology market reached $1.1 billion in
2010. It is expected to reach $1.6 billion in 2011 and it will further grow to
$10.8 billion by 2016, increasing at a compound annual growth rate (CAGR) of
45.8.%
- The global value of the enabled products segment reached $944.7 million in
2010. It is expected to reach $1.4 billion in 2011 and will further grow to
nearly $9.5 billion by 2016 at a CAGR of 46.5%.
- The global value of the core products segment reached $109.4 million in
2010. It is expected to reach $126.8 million in 2011 and to grow to $698.8
million by 2016 at a CAGR of 40.7%.
SUMMARY FIGURE
GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET,
BY PRODUCT TYPE, 2010-2016 ($ MILLIONS)
Source: BCC Research
STUDY GOAL AND OBJECTIVES
BCC's goal for this study is to determine the specific applications and
forecast global market demand for synthetic biology products over a 5-year
period from 2011 to 2016. Our particular interest is to characterize and
quantify the synthetic biology products market potential by product type and
end use market segments. We also analyze the synthetic biology industry
structure, competitors, and intellectual property landscape.
Synthetic biology markets reviewed in this report include enabling products,
biologic components, integrated systems, and enabled products.
Our key objective is to present a comprehensive analysis of the emerging
synthetic biology industry, with an emphasis on products and technologies that
are commercially important in the 2011-to-2016 time period. Market segments
with rapid growth rates are highlighted, as well as those segments with large
market potential. This analysis provides a quantitative basis and market
context for companies to make strategic choices about participation in the
synthetic biology industry.
The study will be particularly useful to companies supplying synthetic genes,
oligonucleotides, DNA sequencing instruments, cell culture media, biofuels,
specialty chemicals, pharmaceuticals, vaccines, microfluidics, and life
sciences tools.
REASONS FOR DOING THE STUDY
Synthetic biology is a rapidly emerging biotechnology discipline with a wide
range of applications. Despite its emerging status, synthetic biology
provides a significant number of near-term commercial opportunities, and the
list of new products and applications is continuously growing. These
applications include specialty chemicals, enzymes, synthetic genes and other
DNA parts, pharmaceuticals, biofuels, and chassis microorganisms.
It is important for companies in industries affected by the developments in
synthetic biology to sort through the many potential applications to identify
near-term commercial opportunities for product development focus. This report
allows companies to prioritize product opportunities, establishing a solid
framework for strategic planning.
Synthetic biology encompasses a wide range of industries including life
science tools, biotechnology, pharmaceuticals, diagnostics, energy, and
chemicals. Because of its wide scope, synthetic biology plays an important
role in the future of the industrial economy.
Ongoing advances in enabling technologies such as DNA synthesis and
sequencing, specialty media, and bioinformatics, as well as a need for
renewable feedstocks, are driving the growth of synthetic biology. Rapid
developments in these multidisciplinary fields promise to advance the
synthetic biology industry and create unique market opportunities. This
report analyzes these trends and their impact on the future markets for
synthetic biology products.
Based on these market and technology dynamics, it is especially timely to
examine the current and future synthetic biology markets.
SCOPE AND FORMAT
The study's scope includes core synthetic biology products (synthetic genes,
other DNA parts, chassis organisms, synthetic cells), enabling technologies
(DNA sequencing, oligonucleotides, specialty media, bioinformatics), and
enabled technologies (biofuels, specialty chemicals, diagnostics,
pharmaceuticals, agriculture) that are already commercial or forecast to be
commercialized within the next 5 years.
We analyze key synthetic biology technologies and products to determine
present and future market status, and forecast growth from 2011 through 2016.
We also discuss strategic alliances, industry structures, competitive
dynamics, patent strategy, and market driving forces.
BCC examines the synthetic biology industry by market segment, including
suppliers of synthetic genes, enzymes, pharmaceutical companies, biofuels, and
specialty chemicals. The role of key strategic alliances from 2009 through
2011 is discussed. Emerging markets including synthetic genes, synthetic
biology-enabled drugs and vaccines, and chassis organisms are analyzed, as
well as metabolically-engineered factories for producing synthetic fuels and
specialty chemicals. The main companies in these fields are highlighted.
METHODOLOGY
BCC surveys key users and producers in each of the end user market segments
and technology fields that will be commercially important during the next 5
years. Discussions with industry thought leaders, as well as secondary
market research was performed.
Based on our analysis, we project the future applications of synthetic biology
technologies in the major end user market segments and by technology type, and
forecast sales revenues for 2011 through 2016.
INFORMATIION SOURCES
BCC surveyed leading synthetic biology, biotechnology, pharmaceutical,
chemical, and energy companies to obtain data for this study. Included were
life science research tools, drug, biotechnology, DNA synthesis and
sequencing, and microfluidics firms, as well as leading life science research
institutions. We also obtained inputs from leading academic and industry
thought leaders. Data from secondary sources included industry, trade, and
government publications.
ANALYST CREDENTIALS
The author, John Bergin, has held business development,
sales, and marketing positions with a Fortune 500 advanced materials company
as well as executive management positions with an emerging nanotechnology
company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S.
Biotechnology, and Masters of Business Administration.
Table of Contents
Synthetic Biology: Emerging Global Markets
Chapter - 1: INTRODUCTION - Complimentary
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- INTENDED AUDIENCE
- SCOPE AND FORMAT
- METHODOLOGY
- INFORMATION SOURCES
- RELATED BCC REPORTS
- ANALYST CREDENTIALS
- BCC ON-LINE SERVICES
- DISCLAIMER
Chapter - 2: SUMMARY
- Table 0: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY PRODUCT TYPE,
THROUGH 2016
- Figure 0: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY PRODUCT TYPE,
2010-2016
Chapter - 3: OVERVIEW
- SYNTHETIC BIOLOGY TECHNOLOGIES COVERED IN THIS REPORT
- WHAT IS SYNTHETIC BIOLOGY?
- DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY
- FORCES DRIVING SYNTHETIC BIOLOGY MARKET GROWTH
- GLOBAL MARKET POTENTIAL FOR SYNTHETIC BIOLOGY PRODUCTS
- LIFE CYCLE STATUS OF PRODUCTS AND TECHNOLOGIES
- THE SYNTHETIC BIOLOGY INDUSTRY
- Table 5: SYNTHETIC BIOLOGY COMPETITORS BY MARKET FOCUS
Chapter - 4: SYNTHETIC BIOLOGY TECHNOLOGIES
- INTRODUCTION
- SYNTHETIC BIOLOGY TECHNOLOGY OVERVIEW
- ENABLING TECHNOLOGIES
- BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS TECHNOLOGIES
- ENABLED TECHNOLOGIES
- PATHWAY ENGINEERING
- SYNTHETIC MICROBIAL CONSORTIA
- RESEARCH AND DEVELOPMENT APPLICATIONS
- BIOFUELS TECHNOLOGIES
Chapter - 5: SYNTHETIC BIOLOGY APPLICATIONS
- INTRODUCTION
- ENABLING TECHNOLOGIES APPLICATIONS
- BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS APPLICATIONS
- ENABLED PRODUCT APPLICATIONS
Chapter - 6: SYNTHETIC BIOLOGY INDUSTRY
- INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN
- INDUSTRY STRUCTURAL FORCES
- PRODUCTS AND TECHNOLOGY LIFE CYCLE
- GENE SYNTHESIS INDUSTRY
- BIOFUELS INDUSTRY
- CHEMICALS INDUSTRY
- ENZYMES INDUSTRY
- PHARMACEUTICALS INDUSTRY
- Table 65: SYNTHETIC BIOLOGY-ENABLED DRUG STRATEGIES
Chapter - 7: SYNTHETIC BIOLOGY MARKETS
- INDUSTRY GROWTH DRIVING FORCES
- MACROECONOMIC FORECASTING ASSUMPTIONS
- SYNTHETIC BIOLOGY MARKETS BY END USER INDUSTRY
- SYNTHETIC BIOLOGY MARKETS BY PRODUCT TYPE
- ENABLED PRODUCTS MARKET
- SYNTHETIC BIOLOGY MARKET BY GEOGRAPHY
Chapter - 8: PATENTS
- INTRODUCTION
- SYNTHETIC BIOLOGY INDUSTRY PATENT ANALYSIS
- PATENT STRATEGY OF SELECTED COMPANIES
Chapter - 9: COMPANY PROFILES
- AGRIVIDA
- ALGENICS
- ALGENOL BIOFUELS
- ALLOPARTIS BIOTECHNOLOGIES, INC.
- ALLYLIX
- AMBRX, INC.
- AMYRIS BIOTECHNOLOGIES, INC.
- ATG BIOSYNTHETICS GMBH
- BASF AG
- BAYER AG
- BIOAMBER INC.
- BIOBASIC INC.
- BIOCALDOL LTD.
- BIOCAT GMBH
- BIONEER CORPORATION
- BIONEXUS INC.
- BIOSEARCH TECHNOLOGIES, INC.
- BIO S&T, INC.
- BIOTICA TECHNOLOGY LTD.
- BLUE MARBLE ENERGY
- BRISTOL MYERS SQUIBB
- BRITISH PETROLEUM
- COBALT TECHNOLOGIES
- CODEXIS, INC.
- DANISCO A/S
- DNA2.0
- DOW CHEMICAL COMPANY
- DRATHS CORPORATION
- E.I DU PONT DE NEMOURS AND COMPANY
- DYADIC INTERNATIONAL
- ENTELECHON GMBH
- EPOCH LIFE SCIENCE, INC.
- EUROFINS MWG OPERON
- EVOLVA SA
- EXXONMOBIL CORPORATION
- FEBIT HOLDING GMBH
- FLUXOME A/S
- GENEMED SYNTHESIS INC.
- GENEWORKS PTY. LTD.
- GENEORACLE, INC.
- GENOMATICA
- GENSCRIPT USA INC.
- GEVO, INC.
- GINKGO BIOWORKS
- GLYCOS BIOTECHNOLOGIES, INC.
- GOODYEAR TIRE & RUBBER
- GREEN BIOLOGICS LTD.
- ILLUMINA, INC.
- INGENZA LTD.
- INTEGRATED DNA TECHNOLOGIES, INC.
- INSTITUTE FOR ONEWORLD HEALTH
- IOGEN CORPORATION
- INTREXON CORPORATION
- JOULE UNLIMITED
- KIVERDI, INC.
- LC SCIENCES
- LIFE TECHNOLOGIES, INC.
- LS9, INC.
- LUMINEX
- MASCOMA
- MERCK & CO.
- METABOLIX INC.
- METRIGEN, INC.
- MODULAR GENETICS
- MORPHOSYS AG
- MYRIANT TECHNOLOGIES
- NEW ENGLAND BIOLABS
- NOVACTA BIOSYSTEMS LTD.
- NOVOZYMES A/S
- OMEGA BIO-TEK, INC.
- OPX BIOTECHNOLOGIES, INC.
- ORIGENE TECHNOLOGIES
- OXITEC LTD.
- PACIFIC BIOSCIENCES
- PFIZER
- PROTERRO INC.
- PROTOLIFE SRL
- QTEROS, INC.
- RENNOVIA, INC.
- ROCHE LIFE SCIENCES
- ROYAL DSM N.V.
- SANGAMO BIOSCIENCES, INC.
- SANOFI AVENTIS
- SAPPHIRE ENERGY
- SCARAB GENOMICS, LLC
- SHANGHAI GENERAY BIOTECH CO., LTD.
- SHANGHAI SHINEGENE MOLECULAR BIO-TECHNOLOGIES, INC.
- SOLAZYME, INC.
- SUTRO BIOPHARMA, INC.
- SWITCHGEAR GENOMICS
- SYNPROMICS LTD.
- SYNTHETIC GENOMICS INC.
- THERMO FISHER SCIENTIFIC
- VERDEZYNE, INC.
- VERENIUM CORPORATION
- VIRAL GENETICS INC.
- ZIOPHARM ONCOLOGY, INC.
List of Tables
- Summary Table: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY PRODUCT TYPE,
THROUGH 2016
- Table 1: SCOPE OF THIS REPORT
- Table 2: FORCES DRIVING THE GROWTH OF SYNTHETIC BIOLOGY
- Table 3: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY END USER INDUSTRY,
THROUGH 2016
- Table 4: SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGE
- Table 5: SYNTHETIC BIOLOGY COMPETITORS BY MARKET FOCUS
- Table 6: SYNTHETIC BIOLOGY DEFINITIONS
- Table 7: SYNTHETIC BIOLOGY HISTORY
- Table 8: PARADIGM SHIFT CAUSED BY SYNTHETIC BIOLOGY
- Table 9: GENETIC ENGINEERING AND SYNTHETIC BIOLOGY COMPARISON
- Table 10: SYNTHETIC BIOLOGY APPLICATIONS BY TECHNOLOGY
- Table 11: IMPORTANCE OF ENABLING TECHNOLOGIES
- Table 12: COSTS TO SEQUENCE AND SYNTHESIZE A HUMAN GENOME, 2001-2018
- Table 13: COMPARISON OF GENE SYNTHESIS TECHNOLOGIES
- Table 14: IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN SYNTHETIC BIOLOGY
- Table 15: MICROARRAY TYPES
- Table 16: DNA MICROARRAY PLATFORM FEATURES
- Table 17: DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS
- Table 18: WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA SEQUENCING
PLATFORMS
- Table 19: BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES
- Table 20: SYNTHETIC BIOLOGY BIOINFORMATICS TECHNOLOGIES
- Table 21: NUCLEIC ACIDS, GENES, AND GENOMES
- Table 22: SYNTHETIC GENES AS A MOLECULAR BIOLOGY TOOL
- Table 23: SYNTHETIC GENES VERSUS PCR CLONING
- Table 24: BIOBRICK PARTS
- Table 25: ATTRIBUTES OF A MINIMAL GENOME
- Table 26: ENABLED TECHNOLOGIES: EXISTING AND NEAR TERM APPLICATIONS
- Table 27: METABOLIC ENGINEERING FOR ARTEMISINIC ACID
- Table 28: APPLICATIONS FOR SYNTHETIC MICROBIAL CONSORTIA
- Table 29: RESEARCH & DEVELOPMENT APPLICATIONS FOR SYNTHETIC BIOLOGY
PRODUCTS
- Table 30: ADVANCED BIOFUELS TYPES
- Table 31: FIRST AND SECOND GENERATION BIOFUELS COMPARED
- Table 32: ENERGY BALANCE OF SELECTED FIRST GENERATION BIOFUEL FEEDSTOCKS
- Table 33: APPROXIMATE COMPOSITION OF CELLULOSIC BIOMASS
- Table 34: SYNTHETIC BIOLOGY STRATEGIES FOR CONVERTING CELLULOSIC BIOMASS
INTO ETHANOL
- Table 35: BIOMASS ECONOMICS
- Table 36: BIODIESEL YIELDS OF SELECTED CROPS
- Table 37: EFFICIENCIES OF VARIOUS FUELS
- Table 38: IODINE NUMBER OF VARIOUS OILS
- Table 39: CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS
- Table 40: SYNTHETIC BIOLOGY PRODUCTS IMPACTED BY ENABLING TECHNOLOGIES
- Table 41: BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS NEAR-TERM
APPLICATIONS
- Table 42: SYNTHETIC GENES NEAR-TERM APPLICATIONS
- Table 43: E. COLI AS A CHASSIS ORGANISM
- Table 44: SYNTHETIC BIOLOGY-ENABLED DRUG CLASSES
- Table 45: DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC
BIOLOGY PRODUCTS
- Table 46: SYNTHETIC BIOLOGY-ENABLED PHARMACEUTICAL APPLICATIONS
- Table 47: SYNTHETIC BIOLOGY-ENABLED DIAGNOSTICS APPLICATIONS
- Table 48: SYNTHETIC BIOLOGY-ENABLED BIOFUELS APPLICATIONS
- Table 49: GROWTH STATUS OF SPECIALTY VERSUS DROP-IN BIOFUELS, 2000-2020
- Table 50: SYNTHETIC BIOLOGY-ENABLED CHEMICALS APPLICATIONS
- Table 51: SYNTHETIC BIOLOGY-ENABLED ENGINEERED PLANTS AND INSECTS
APPLICATIONS
- Table 52: SYNTHETIC BIOLOGY-ENABLED PRODUCTION PROCESSES APPLICATIONS
- Table 53: SYNTHETIC BIOLOGY INDUSTRY STRUCTURAL FORCES
- Table 54: SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGES
- Table 55: GENE SYNTHESIS WORKFLOW
- Table 56: SYNTHETIC GENE COMPANY ESTIMATED 2010 MARKET SHARES
- Table 57: SYNTHETIC GENE KEY COMPETITOR STRATEGIES
- Table 58: GENE SYNTHESIS MARKET FACTORS OF DIFFERENTIATION
- Table 59: BIOFUELS: FEEDSTOCKS, PRODUCTION AND PRODUCTS
- Table 60: BIOFUELS FEEDSTOCKS: RELATIVE SUPPLY VOLUME AND COSTS
- Table 61: SYNTHETIC BIOLOGY BIOFUELS COMPANY STRATEGIES
- Table 62: SYNTHETIC BIOLOGY-ENABLED CHEMICALS APPLICATIONS
- Table 63: VALUE-ADDED IN SELECTED END MARKETS
- Table 64: ENZYME COMPANY KEY ALLIANCES
- Table 65: SYNTHETIC BIOLOGY-ENABLED DRUG STRATEGIES
- Table 66: SYNTHETIC BIOLOGY INDUSTRY ACQUISITIONS, 2010 - 2011
- Table 67: STRATEGIC ALLIANCES, 2009 - 2011
- Table 68: SYNTHETIC BIOLOGY GROWTH DRIVING FORCES
- Table 69: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY END USER INDUSTRY,
THROUGH 2016
- Table 70: GLOBAL VALUE OF R&D MARKET, BY PRODUCT TYPE, THROUGH 2016
- Table 71: GLOBAL VALUE OF DIAGNOSTICS/PHARMACEUTICALS MARKET, BY PRODUCT
TYPE, THROUGH 2016
- Table 72: GLOBAL VALUE OF CHEMICALS MARKET, BY PRODUCT TYPE, THROUGH 2016
- Table 73: GLOBAL VALUE OF ENERGY MARKET, BY PRODUCT TYPE, THROUGH 2016
- Table 74: GLOBAL VALUE OF AGRICULTURE MARKET, BY PRODUCT TYPE, THROUGH 2016
- Table 75: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY PRODUCT TYPE,
THROUGH 2016
- Table 76: GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLING PRODUCTS, BY TYPE,
THROUGH 2016
- Table 77: GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLING PRODUCTS, BY
INDUSTRY, THROUGH 2016
- Table 78: GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET, BY TYPE, THROUGH 2016
- Table 79: GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET, BY INDUSTRY, THROUGH
2016
- Table 80: BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS NEAR-TERM
APPLICATIONS
- Table 81: GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET, BY TYPE, THROUGH 2016
- Table 82: GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET, BY INDUSTRY, THROUGH
2016
- Table 83: BIODIESEL FUEL PERFORMANCE COMPARISON
- Table 84: ARTEMISININ DRUG PRODUCTION COMPARISON
- Table 85: GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLED PRODUCTS MARKET, BY
INDUSTRY, THROUGH 2016
- Table 86: GLOBAL VALUE OF ENABLED DIAGNOSTIC AND PHARMACEUTICALS MARKET,
BY INDUSTRY, THROUGH 2016
- Table 87: GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED DIAGNOSTICS MARKET, BY
INDICATION, THROUGH 2016
- Table 88: GLOBAL VALUE OF ENABLED PHARMACEUTICALS MARKET, BY DRUG CLASS,
THROUGH 2016
- Table 89: GLOBAL VALUE OF ENABLED CHEMICALS MARKET, BY PRODUCT TYPE,
THROUGH 2016
- Table 90: ADVANCED BIOFUEL GROWTH DRIVING FACTORS
- Table 91: PUBLIC AND PRIVATE FUNDING FOR SELECTED BIOFUELS COMPANIES
- Table 92: GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED BIOFUELS MARKET, BY
FUEL TYPE, THROUGH 2016
- Table 93: GLOBAL VALUE OF AGRICULTURE MARKET, BY APPLICATION, THROUGH 2016
- Table 94: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY GEOGRAPHY, THROUGH
2016
- Table 95: GLOBAL VALUE OF ENABLING PRODUCTS MARKET, BY GEOGRAPHY, THROUGH
2016
- Table 96: GLOBAL VALUE OF CORE PRODUCTS MARKET, BY GEOGRAPHY, THROUGH 2016
- Table 97: GLOBAL VALUE OF ENABLED PRODUCTS MARKET, BY GEOGRAPHY, THROUGH
2016($ MILLIONS)
- Table 98: SYNTHETIC BIOLOGY PATENT SCOPE
- Table 99: SYNTHETIC BIOLOGY FOUNDATIONAL PATENTS
- Table 100: PATENT DESCRIPTION BY COMPANY
- Table 101: AGRIVIDA TECHNICAL APPROACH
- Table 102: AMYRIS SPECIALTY CHEMICALS STRATEGY
- Table 103: AMYRIS BIODIESEL ADVANTAGES
- Table 104: STRUCTURE-FUNCTION APPROACH FOR RAPAMYCIN
- Table 105: EVOLVA'S GENETIC CHEMISTRY PLATFORM
- Table 106: EVOLVA STRATEGIC ALLIANCES
- Table 107: EVOLVA PRODUCT PIPELINE
- Table 108: INTREXON ULTRAVECTOR PARTS INVENTORY EXAMPLES
- Table 109: MIREL'S COMPETITORS IN BIOPLASTICS
- Table 110: SANGAMO STRATEGIC ALLIANCES
- Table 111: SOLAZYME STRATEGIC ALLIANCES
- Table 112: SYNTHETIC GENOMICS STRATEGIC ALLIANCES
List of Figures
- Summary Figure: GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY PRODUCT TYPE,
2010-2016
- Figure 1: SYNTHETIC BIOLOGY VALUE-ADDED CHAIN
- Figure 2: FROM THE NATURAL TO THE ARTIFICIAL
- Figure 3: SCALE OF SYNTHETIC BIOLOGY
- Figure 4: SCHEMATIC OF GENE SYNTHESIS TECHNOLOGIES
- Figure 5: MICROARRAYS IN GENE SYNTHESIS
- Figure 6: ROLE OF PROMOTERS AND REPORTERS IN SYNTHETIC BIOLOGY SYSTEMS
- Figure 7: HOW SYNTHETIC BIOLOGY CREATES ENABLED PRODUCTS
- Figure 8: CELLULOSIC ETHANOL PRODUCTION SCHEMATIC
- Figure 9: INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH SYNTHETIC BIOLOGY
LEVERAGE POINTS
- Figure 10: MARKET FORECAST SCENARIO TABLE
- Figure 11: NUMBER OF PATENTS BY COMPANY
- Figure 12: PATENTS BY COMPANY AND SUBCLASS
2016年合成生物學的全球市場將達到108億美元規模
2011年12月14日
Global Information, Inc.已開始銷售BCC Research所發行的報告書「Synthetic Biology: Emerging Global Markets (合成生物學:新的全球的市場)」
2011年合成生物學的全球市場超過16億美元規模，之後以複合年成長率(CAGR)45.8％擴大，預估2016年時將達到108億美元。
全球的合成生物學市場分成授權技術與產品、主要產品及應用產品3個部門。
利用授權技術及關聯產品作為牽引合成生物產業發展的原動力。
標準DNA零件、合成基因及有機底盤生成等主要產品及技術，變成是細胞工廠和系統生產應用產品的主要工具。
合成生物學的應用產品以醫藥、診斷、化學藥品、生物燃料及農業的龐大下游市場機會為目標。這些下游市場年間各自有幾百億美元的市場價值。
應用產品是最大的市場部門，2011年變成14億美元規模，之後以CAGR 46.5％成長，預估2016年時將達到約95億美元。
2011年授權及主要產品的市場價值各自為1億1,090萬美元與1億2,680萬美元，之後以42.6％及40.7％成長，預計2016年時達到6億5,370萬美元與6億9,880萬美元。
對受到合成生物學發展影響的產業企業來說，為了區分許多潛在的應用，致力於產品開發，特別指定不久將來的商機就變得很重要。
本報告書將企業的產品機會排定優先次序，有助於確實建構策略性計劃的組織。
|
